Surface Oncology, Inc. (SURF)
Market Cap | 46.52M |
Revenue (ttm) | n/a |
Net Income (ttm) | -89.53M |
Shares Out | 60.72M |
EPS (ttm) | -1.54 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 100,173 |
Open | 0.764 |
Previous Close | 0.762 |
Day's Range | 0.740 - 0.796 |
52-Week Range | 0.555 - 2.150 |
Beta | 1.68 |
Analysts | Strong Buy |
Price Target | 4.50 (+487.31%) |
Earnings Date | Aug 2, 2023 |
About SURF
Surface Oncology, Inc., a clinical-stage immuno-oncology company, engages in the development of cancer therapies in the United States. The company develops various antibodies that include NZV930, a fully human immunoglobulin isotype G4 monoclonal antibody for the production of extracellular adenosine; SRF617, a fully human IgG4 monoclonal antibody that inhibits CD39 enzymatic activity for the production of adenosine and the breakdown of adenosine triphosphate; SRF388 targeting interleukin 27; GSK4381562, an antibody targeting CD112R, an inhibit... [Read more]
Financial Performance
In 2022, SURF's revenue was $30.00 million, an increase of 1016.49% compared to the previous year's $2.69 million. Losses were -$63.59 million, -18.98% less than in 2021.
Financial StatementsAnalyst Forecast
According to 2 analysts, the average rating for SURF stock is "Strong Buy." The 12-month stock price forecast is $4.5, which is an increase of 487.31% from the latest price.
News

Surface Oncology Reports Financial Results and Corporate Highlights for First Quarter 2023
Updated clinical data from Phase 2 studies evaluating SRF388 in both liver and lung cancer expected in the second quarter of 2023

Surface Oncology Presents New Preclinical Data on SRF114, a fully human anti-CCR8 antibody, at the AACR Annual Meeting 2023
– New in vivo data show SRF114 promotes a pro-inflammatory tumor microenvironment resulting in robust antitumor activity in mouse models – – New in vivo data show SRF114 promotes a pro-inflammatory tu...

Surface Oncology to Present New Preclinical SRF114 Data at the American Association for Cancer Research (AACR) Annual Meeting 2023
CAMBRIDGE, Mass., March 16, 2023 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenv...

Surface Oncology Reports Financial Results and Corporate Highlights for Fourth Quarter and Full Year 2022
SRF388 clinical program advancing well; updated clinical data expected in the first half of 2023

Surface Oncology to Participate in the Cowen 43rd Annual Health Care Conference
CAMBRIDGE, Mass., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvi...

Surface Oncology to Participate in the 2023 Guggenheim Oncology Days Conference
CAMBRIDGE, Mass., Feb. 02, 2023 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvi...

Surface Oncology Announces First Patient Dosed in a Phase 1/2 Study Evaluating SRF114, a Potential Best-In-Class Anti-CCR8 Antibody, in Patients with Advanced Solid Tumors
SRF114 is designed to preferentially deplete CCR8 + Treg cells within the tumor microenvironment and has demonstrated highly specific CCR8-exclusive binding and reduced tumor growth in pre-clinical st...

Surface Oncology to Present Non-clinical Data for SRF388 and SRF114 at the Society for Immunotherapy of Cancer 2022 Annual Meeting
Data further support SRF388 and SRF114 clinical development programs Data further support SRF388 and SRF114 clinical development programs

Surface Oncology Announces Promising SRF388 Monotherapy Data in Non-Small Cell Lung Cancer (NSCLC), Opening Second Stage of Monotherapy Trial and NSCLC Pembrolizumab Combination Cohort
– Two confirmed partial responses to SFR388 monotherapy treatment in squamous NSCLC; third patient with NSCLC experienced durable disease stabilization for over a year –

VIB and Surface Oncology Announce Publication in Cell Reports Revealing IL-27 Structure and the Mechanism of Action for SRF388
– Study reveals the structural basis of receptor activation and signaling by IL-27 cytokine – – Study elucidates how SRF388 binds to IL-27 to prevent interaction with the IL-27 receptor, inhibiting th...

Surface Oncology to Present Preclinical Data Highlighting the IL-27 Gene Expression Signature in Treatment-Resistant Cancers at the 10th Annual International Cytokine and Interferon Society Meeting
- New preclinical data indicate IL-27 induces a gene expression signature that has been associated with resistance to chemotherapy, radiotherapy, and checkpoint inhibition -

Surface Oncology to Participate in the Baird 2022 Global Healthcare Conference
CAMBRIDGE, Mass., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenv...

Surface Oncology to Participate in the Gilmartin Group Emerging Growth Company Showcase
CAMBRIDGE, Mass., Aug. 24, 2022 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvi...

Surface Oncology Reports Financial Results and Business Highlights for Second Quarter 2022
– SRF388 clinical data presented at 2022 ASCO Annual Meeting demonstrated monotherapy responses in two different indications, combination activity and notable disease stabilization –

Surface Oncology to Participate in the 2022 Wedbush PacGrow Healthcare Conference
CAMBRIDGE, Mass., Aug. 01, 2022 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvi...

Surface Oncology Appoints Carsten Brunn to Board of Directors
CAMBRIDGE, Mass., June 29, 2022 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvi...

Surface Oncology Announces Publication of New Study Demonstrating the Role of the IL-27 Pathway in Hepatocellular Carcinoma
- Non-clinical findings further support the potential of SRF388 to treat patients suffering from liver cancer -

Surface Oncology Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass., June 03, 2022 (GLOBE NEWSWIRE) -- Surface Oncology, Inc. (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor mic...

Surface Oncology to Participate in Upcoming Investor Conferences
CAMBRIDGE, Mass., June 01, 2022 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvi...

Surface Oncology to Present New SRF388 Clinical Data at 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
– SRF388 demonstrated clinical activity in multiple solid tumor types with three confirmed partial responses across NSCLC, RCC and HCC –

Surface Oncology Reports Financial Results and Corporate Highlights for First Quarter 2022
– Cash runway extended into 2024 –

Surface Oncology to Present Clinical Update on SRF388 at American Society of Clinical Oncology Annual Meeting
CAMBRIDGE, Mass., April 27, 2022 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenv...

Surface Oncology Named one of the 2022 Best Places to Work by Boston Business Journal
CAMBRIDGE, Mass., April 21, 2022 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenv...

Surface Oncology Announces Initiation of Phase 2 Studies Evaluating SRF388 in Patients with Hepatocellular Carcinoma and Non-Small-Cell Lung Cancer
Randomized Phase 2 clinical study evaluating SRF388 in first-line hepatocellular carcinoma in clinical collaboration with Roche

Surface Oncology Presents New SRF388 Data at the American Association for Cancer Research (AACR) Annual Meeting 2022
Poster presentation highlights translational work supporting recommended dosing for SRF388 Phase 2 trials Poster presentation highlights translational work supporting recommended dosing for SRF388 Pha...